3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
7
NIH
2
NETWORK
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
40
Neoplasms
8
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Quality of Life
1
Neoplasms by Site
1
Multiple Endocrine Neoplasia Type 1
1
Hot Flashes
1
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Gynecomastia
1
Endometrial Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms, Male
1
Breast Diseases
1
Breast Cancer Subjects
1
Breast Cancer Metastatic
1
Breast Cancer Female
1
Bone Density
1
Advanced Metastatic Breast Cancer
1
Advanced Cancer
1
Interventions
exemestane
2
Letrozole
2
seviteronel
1
sargramostim
1
ribociclib
1
methyl N-acetylsibirosaminide
1
elacestrant
1
Trastuzumab
1
Tamoxifen
1
Suspensions
1
Receptor Protein-Tyrosine Kinases
1
Presenilin-1
1
Pemetrexed
1
Leuprolide
1
Injections
1
HER2 peptide (369-377)
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Goserelin
1
Fentanyl
1
Anastrozole
1
90Y-octreotide, DOTA-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Breast Neoplasms, Male
×
Tamoxifen
×
Clear all
NCT06492616
2026-05-27
ELEGANT
Stemline Therapeutics, Inc.
Phase 3
Recruiting
4,220 enrolled